<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529174</url>
  </required_header>
  <id_info>
    <org_study_id>HTI-003</org_study_id>
    <nct_id>NCT04529174</nct_id>
  </id_info>
  <brief_title>Oral Nutritional Supplement Effect on HDL Function</brief_title>
  <official_title>Evaluation of an Oral Nutritional Supplement for Effect on Total High-Density Lipoprotein (HDL) Cholesterol, HDL Functionality, Particle Size and Number</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metagenics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metagenics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL&#xD;
      particle size and HDL particle number (HDL-P)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind Placebo controlled trial. Dietary</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL-FX test HDL-FX test</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>Reverse Cholesterol Transport (RCT)(CEC) with Cleveland Heart Lab (CHL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL mapping</measure>
    <time_frame>Change from Baselineto End of study (week 12)</time_frame>
    <description>HDL mapping with Boston Heart Lab (BHL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myloperoxidase (MPO)</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>measured with Quest Lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LP-PLA-2 test</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>Measured with Quest Lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>24 hour recall</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>measured in pounds (Lbs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>measured in kg/m2</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>measured in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure (systolic/diastolic)</measure>
    <time_frame>Change from Baseline to End of Study (week 12)</time_frame>
    <description>measured in mm Hg</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>HDL</condition>
  <arm_group>
    <arm_group_label>Active HDL supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CardioLux™HDL</intervention_name>
    <description>Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).&#xD;
Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.&#xD;
Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.&#xD;
Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)</description>
    <arm_group_label>Active HDL supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).&#xD;
Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.&#xD;
Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.&#xD;
Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and non-pregnant female patients or female patients of childbearing age on&#xD;
             contraception age 18-80years.&#xD;
&#xD;
          -  Total HDL level 38mg/dL or lower in men and HDL 45 mg/dL or lower in women and a low&#xD;
             HDL-P defined as less than 7000 by Spectracell LPP Plus.&#xD;
&#xD;
          -  CHL HDL Fx score equal to or greater than 0.9.&#xD;
&#xD;
          -  Patients will remain on their present diet, exercise program, medications (except for&#xD;
             those who alter serum lipids) sleeping habits, alcohol intake, caffeine intake,&#xD;
             smoking amount and emotional status as best as possible related to stress and anxiety&#xD;
             and maintain body weight at baseline visit as best as possible to avoid confounding&#xD;
             variables.&#xD;
&#xD;
          -  No other lipid lowering supplement can be taken during the study.&#xD;
&#xD;
          -  All lipid lowering supplements must have been discontinued at least 30 days prior t o&#xD;
             study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Females of childbearing age not on an accepted contraception control method&#xD;
&#xD;
          -  Previous myocardial infarction within 5 years&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Previous stroke or TIA within 5 years&#xD;
&#xD;
          -  Uncompensated congestive heart failure&#xD;
&#xD;
          -  Previous PCTA or stent within 5 years&#xD;
&#xD;
          -  Previous CABG within 5 years&#xD;
&#xD;
          -  Patients on statins, fibrates, or other lipid lowering medications or any supplement&#xD;
             known to affect serum lipids.&#xD;
&#xD;
          -  Known or previous cancer within 5 years&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Kidney disease as defined by serum creatinine over 2.5 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Houston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hypertension Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hypertension Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDL cholesterol</keyword>
  <keyword>HDL function</keyword>
  <keyword>HDL particle</keyword>
  <keyword>Dietary supplement</keyword>
  <keyword>Nutraceutical</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

